ARID1A and ovarian cancer: In the treatment of ovarian cancer, the combination of temozolomide and a PARP inhibitor exploits the specific DNA damage repair status of ARID1A-inactivated ovarian cancers to suppress tumor growth (Yu et al., 2023).